GenVivo
GenVivo identifies GEN-310 as an in vivo CAR-T/NK program for B-cell malignancies. Its October 2025 corporate presentation classifies GEN-310 as preclinical. Clinical work on separate immunocytokine vectors should not be used to upgrade this CAR program.
Corporate information
- Company entity
- GenVivo
- Headquarters / principal office
- Public office in San Marino, California, United States ↗
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://genvivoinc.com/pipeline/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
GenVivo identifies GEN-310 as an in vivo CAR-T/NK program for B-cell malignancies. Its October 2025 corporate presentation classifies GEN-310 as preclinical. Clinical work on separate immunocytokine vectors should not be used to upgrade this CAR program.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.